CN105395919A - Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition - Google Patents
Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition Download PDFInfo
- Publication number
- CN105395919A CN105395919A CN201510816925.8A CN201510816925A CN105395919A CN 105395919 A CN105395919 A CN 105395919A CN 201510816925 A CN201510816925 A CN 201510816925A CN 105395919 A CN105395919 A CN 105395919A
- Authority
- CN
- China
- Prior art keywords
- extract
- auricularia
- effect
- blood fat
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 142
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000000694 effects Effects 0.000 title claims abstract description 55
- 210000004369 blood Anatomy 0.000 title claims abstract description 45
- 239000008280 blood Substances 0.000 title claims abstract description 45
- 230000001603 reducing effect Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 241000233866 Fungi Species 0.000 title abstract description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 34
- 241000221377 Auricularia Species 0.000 claims description 78
- 244000113306 Monascus purpureus Species 0.000 claims description 29
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 29
- 229940057059 monascus purpureus Drugs 0.000 claims description 28
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 27
- 235000011201 Ginkgo Nutrition 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- -1 filters Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000002604 ultrasonography Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000218628 Ginkgo Species 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 13
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 12
- 210000002966 serum Anatomy 0.000 abstract description 9
- 150000004676 glycans Chemical class 0.000 abstract description 8
- 229920001282 polysaccharide Polymers 0.000 abstract description 8
- 239000005017 polysaccharide Substances 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 5
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 2
- 229940041514 candida albicans extract Drugs 0.000 abstract 2
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 abstract 2
- 235000020717 hawthorn extract Nutrition 0.000 abstract 2
- 229940051810 licorice root extract Drugs 0.000 abstract 2
- 235000020725 licorice root extract Nutrition 0.000 abstract 2
- 239000012138 yeast extract Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 229930003944 flavone Natural products 0.000 description 8
- 235000011949 flavones Nutrition 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000000055 hyoplipidemic effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000008802 xuezhikang Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- MKDKGLNKTMDNHY-WXUKJITCSA-N (e)-n,5-dihydroxy-n-[3-[5-[3-[hydroxy-[(e)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide Chemical compound OCCC(/C)=C/C(=O)N(O)CCCC1NC(=O)C(CCCN(O)C(=O)\C=C(/C)CCO)NC1=O MKDKGLNKTMDNHY-WXUKJITCSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QLJODMDSTUBWDW-BXMDZJJMSA-N mevinolinic acid Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C=C21 QLJODMDSTUBWDW-BXMDZJJMSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition containing black fungus extract and having the effect of reducing blood fat and a preparation method of the composition. The composition is prepared from 400-1100 mg of black fungus polysaccharide, 35-100 mg of black fungus melanin, 95-350 mg of red-rice-yeast extract, 75-180 mg of ginkgo leaf extract, 55-170 mg of hawthorn extract, 55-170 mg of pollen typhae extract and 70-170 mg of licorice root extract. The composition adopts multiple types of bio-active substances such as the black fungus extract, the red-rice-yeast extract, the ginkgo leaf extract, the hawthorn extract and the pollen typhae extract which have the function of reducing the blood fat, the effect of reducing the blood fat is enhanced, the licorice root extract which has the functions of detoxifying and toxin expelling is added to serve as a component of the composition, and the synergetic effect and the effects of detoxifying and toxin expelling are achieved. Obvious synergistic action in the aspects of reducing serum total cholesterol, serum triglyceride and low density lipoprotein cholesterol exists, and the composition has the obvious advantage in the aspect of reducing side effects.
Description
Technical field
The present invention relates to a kind of composition and method of making the same with effect for reducing blood fat.
Background technology
Hyperlipidemia serious threat health.Hyperlipidemia directly can cause the cardiovascular and cerebrovascular diseases such as cerebral infarction, thromboangiitis, obesity, atherosclerosis, fatty liver, cholelithiasis and atherosclerosis coronary heart disease, and cardiovascular and cerebrovascular disease is one of human maximum cause of the death, the whole world about has 1,200 ten thousand people to die from cardiovascular and cerebrovascular disease every year, and therefore the prevention and therapy of hyperlipemia is most important.The current treatment to hyperlipidemia is that primary and secondary effect is large with Western medicine, therefore develops evident in efficacy, low being of great significance with the food puted prevention first or medicine tool of side effect.
Complicated component in compound preparation for reducing blood fat, more or less has certain side effect.Therefore develop and really there is blood fat reducing function and the health product had no side effect or medicine tool are of great significance and good application prospect.
Auricularia is the dietotherapeutic fungus of Eumycota Basidiomycetes Auriculariale Auriculariaceae Auricularia, containing the various active such as polysaccharide, melanin composition.Traditional medicine is recorded, Auricularia has " property flat, sweet in the mouth ", " QI invigorating is not hungry, strong will of making light of one's life by commiting suicide ", " lung heat clearing lung moistening ", " sharp the five internal organs, toxin expelling gas " effect.Modern medicine study proves, Auricularia has and improves the effect such as immunity, defying age, anticancer, radioprotective, antithrombus formation, blood fat reducing, blood sugar lowering, lifting digestion function of stomach and intestine.Auricularia, no matter in the prevention of disease, treatment or daily health caring, all highlights that it is original, is difficult to many effects of substituting.The mechanism that Auricularia has a hypolipidemic activity is that Auricularia can enhancing human body immunity power, and immunity moderation function, maintains the normal operation of each organ in human body, improves the activity participating in enzyme, promotes the normal circulation effect of liver and gall.Make various composition in blood fat reach normal condition like this, thus reduce blood fat accumulating amount in blood, ensure health.
The hypolipidemic activity composition Study of current Auricularia mainly concentrates on polysaccharide, and as follows for the shortcoming of the conventional aqueous extraction-alcohol precipitation technology of Auricularia polycose extraction: 1. yield is lower, and cost is higher, Auricularia polycose extract yield is generally 3 ~ 5%, and mostly be laboratory stage, cost is higher, is difficult to amplify produce.2. because high temperature when extracting causes the hypolipidemic activity of effective ingredient to reduce, its extensive use is limited.
Summary of the invention
The object of this invention is to provide a kind of containing Auricularia extract, the composition and method of making the same with effect for reducing blood fat, said composition contains Auricularia extract, Monas cuspurpureus Went extract, Folium Ginkgo extract, Fructus Crataegi extract, Pollen Tyjphae extract, Radix Glycyrrhizae extract, there is effect for reducing blood fat, and its lipid-lowering effect is significantly better than being used alone Auricularia extract, Monas cuspurpureus Went extract, Folium Ginkgo extract, Fructus Crataegi extract or Radix Glycyrrhizae extract, has the effect of Synergistic, Synergistic attenuation.
The object of the invention is to be achieved through the following technical solutions:
Containing Auricularia extract, a compositions with effect for reducing blood fat, consist of the following composition: Auricularia polycose 400 ~ 1100mg, Auricularia melanin 35 ~ 100mg, Monas cuspurpureus Went extract 95 ~ 350mg, Folium Ginkgo extract 75 ~ 180mg, Fructus Crataegi extract 55 ~ 170mg, Pollen Tyjphae extract 55 ~ 170mg, Radix Glycyrrhizae extract 70 ~ 170mg.
Above-mentioned containing Auricularia extract, the preparation method with the compositions of effect for reducing blood fat, comprise the following steps:
(1) Auricularia is pulverized, even by the deionized water and stirring of 30 ~ 60 times of volumes, place 1 ~ 3h, room temperature adopts High Pressure Difference method (solution is forced into 1.0 ~ 1.5Mpa, and rapid release of pressure is to atmospheric pressure state in 0.1 ~ 0.3s) to extract 1 ~ 3 time, filters, filter vacuum concentrating under reduced pressure, dry, pulverize, obtain Auricularia polycose extract; The sodium hydroxide solution adjustment solution ph that filtering residue adds 2 ~ 5 times of volumes is 10.0 ~ 11.0, and leave standstill 1 ~ 2h, filter, supernatant hydrochloric acid adjusted to ph is 3.0 ~ 3.5, leaves standstill 1 ~ 2h, and filter, pellet frozen dry, pulverize, and obtains Auricularia melanin.
(2) Folium Ginkgo, Fructus Crataegi and Pollen Typhae all prepare extract according to following extraction process: raw material pulverizing, be extract 2 ~ 3 times under the alcoholic solution ultrasound wave 200 ~ 500W of 50 ~ 95% by 10 ~ 20 times of volume fractions, each 0.5 ~ 1.0h, merge extractive liquid, filters, filtrate recycling ethanol, concentrated, dry, pulverize, obtain alcohol extract.
(3) the cholamine solution (0.1% ammonia, 25% ethanol) adding 6 ~ 20 times of volumes in Radix Glycyrrhizae carries out reflux, extract, 1 ~ 2h at 70 ~ 90 DEG C of temperature, filters, and dries, and pulverizes, obtains Radix Glycyrrhizae extract.
(4) Monas cuspurpureus Went is pulverized, and adopts the alcoholic solution of 60 ~ 85% of 15 ~ 25 times of volumes, extracts 2 ~ 3 times, each 0.5 ~ 1.0h, merge extractive liquid, under ultrasound wave 200 ~ 500W, filters, filtrate recycling ethanol, concentrated, dry, pulverize, obtains alcohol extract.
(5) Auricularia polycose, Auricularia melanin, Fructus Crataegi extract, Semen Ginkgo extrac, Radix Glycyrrhizae extract, Pollen Tyjphae extract and Monas cuspurpureus Went extract are mixed, obtain containing Auricularia extract, the compositions with effect for reducing blood fat.
In the present invention, described Auricularia raw material adopts black 29 kinds to carry out the Auricularia sporophore of autumn culture production in Shangzhi City, Heilongjiang Province Ya Buli area, finds that the Auricularia that the functional component of this raw material is all produced than other areas as Auricularia polycose and melanin content is high through comparative analysis.
In the present invention, Auricularia polycose content 30 ~ 40% (after polysaccharide solution ultrafiltration, adopting Phenol sulfuric acid procedure to measure) in described Auricularia extract, melanin content 3%.
In the present invention, described Auricularia polycose and melanic purity are 30 ~ 40%.
In the present invention, in described Monas cuspurpureus Went extract, effective ingredient Monacolin-K (lovastatin) content reaches more than 1.8% (HPLC method), and wherein open loop (acid) Monacolin-K content accounts for more than 85%.
In the present invention, ginkgetin >=30% (HPLC method) in described Folium Ginkgo extract, Ginkgo total lactones >=8% (HPLC method), ginkgoic acid≤3ppm.The assay of total flavonoids is with reference to " Chinese Pharmacopoeia " Folium Ginkgo extract method, and in compositions, general flavone content adopts high-pressure liquid phase chromatogram therapy determining.
In the present invention, glycyrrhizic acid content more than 15% in described Radix Glycyrrhizae extract, triterpenes and flavone compound total content 20 ~ 30%, Polyhydroxy phenol content 5 ~ 35%.
In the present invention, general flavone content 20 ~ 25% (HPLC method) in described Pollen Tyjphae extract.
In the present invention, general flavone content 3 ~ 25% in described Fructus Crataegi extract.
In the present invention, the grinding particle size of described Auricularia is 150 ~ 240 orders, optimal granularity 200 order.
In the present invention, the grinding particle size of described Folium Ginkgo, Fructus Crataegi, Pollen Typhae and Monas cuspurpureus Went is 100 ~ 150 orders.
Monas cuspurpureus Went is produced by Fermentation Condition of Monascus spp, and Fermentation Condition of Monascus spp can produce multiple metabolite, mainly contains monascorubin, enzymes activity material, material for lowering blood pressure etc.Monas cuspurpureus Went extract to be applied in China with a long history, be used to wine brewing from ancient times, make the food coloring such as vinegar, roast duck.Modern medicine finds that Monas cuspurpureus Went has the effect reducing cholesterol.Because the effective ingredient playing effect for reducing blood fat in Monas cuspurpureus Went is not only Monacolin class (lovastatin), also comprise hydroxy acid lovastatin, ergosterol, pigment, γ-aminobutyric acid, Dimerumicacid etc. and other compositions, because other compositions of Monas cuspurpureus Went extract are also playing the effect of its uniqueness, therefore the action effect of Monas cuspurpureus Went extract in blood fat reducing, anticancer and antioxidation may be greater than the effect of alone lovastatin.
Folium Ginkgo is the dried leaves of Ginkgoaceae plant Ginkgo biloba, has the effects such as invigorating blood circulation is tired, removing obstruction in the collateral to relieve pain, is used for cardiovascular and cerebrovascular disease clinically.Up to the present, in Folium Ginkgo, separation obtains the compositions such as flavone, terpene lactones, organic acid, aminoacid, polysaccharide.Total flavones and terpene lactone, as the characteristic chemical constituent in Folium Ginkgo, have clear and definite biological activity.
Fructus Crataegi is rosaceous plant, and containing various bioactivators, as triterpenic acid, flavone etc., wherein flavones ingredient has the pharmacological actions such as blood pressure lowering, blood fat reducing, increase coronary flow, heart tonifying, arrhythmia.According to the pharmacological action of Fructus Crataegi, now existing a lot of Fructus Crataegi and Fructus Crataegi compound preparation are applied to and clinically treat the cardiovascular disease such as hyperlipidemia, coronary heart diseases and angina pectoris, arrhythmia, China's Hawthorn Resources enriches, with low cost, has good value of exploiting and utilizing.
Pollen Typhae is the dry pollen of Typhaceae plant or congener, has hemostasis, blood stasis dispelling, treating stranguria function, for the control of cardiovascular and cerebrovascular disease.
Radix Glycyrrhizae extract is prevented and treated hyperlipemia, antiviral, is prevented and treated acquired immune deficiency syndrome (AIDS), anticancer, strengthen Culture in vitro and attenuation toxin expelling effect, the effective constituent that mainly contains of Radix Glycyrrhizae is glycyrrhizic acid and glycoside unit enoxolone.
Tool of the present invention has the following advantages:
1) in Auricularia extract, crude polysaccharides extract yield reaches more than 12 ~ 18%, purity more than 30%, and is extract at low temperature, fully remains biological activity; Melanin extraction ratio more than 3%, purity more than 40%.
2) in the present invention, compositions adopts the multiple bioactive substances with hypolipemic function such as Auricularia extract, Monas cuspurpureus Went extract, Folium Ginkgo extract, Fructus Crataegi extract, Pollen Tyjphae extract, enhance lipid-lowering effect, and add there is detoxication and toxicant eliminating function function Radix Glycyrrhizae extract as compositions, there is the effect of Synergistic, attenuation toxin expelling.In reduction serum total cholesterol, serum triglycerides and low-density lipoprotein cholesterol, there is obvious concertedness effect, in reduction side effect, there is clear superiority.According to blood fat reducing test operation in national function of health food test, result shows that compositions is significantly better than being used alone Auricularia extract, Monas cuspurpureus Went extract or Folium Ginkgo extract in lipid-lowering effect.
3) Auricularia extract adopts efficient high-pressure difference low temperature continous way extraction and isolation concentration technique, omnidistancely adopts physics mode, extract at low temperature, and the high and ecosystem realizing active component of extraction ratio retains.Height pressure reduction extractive technique makes cell instant exploding, fully contacts, the polysaccharide of in Auricularia more than 85% is all extracted, make polysaccharide yield reach 12 ~ 18% with solvent.
4) said composition proves to have auxiliary antilipemic effect through animal experiment and human experiment result, can be applicable to Chinese patent medicine, health food or food, reduce cholesterol and blood viscosity, promote the microcirculation of cardiovascular and cerebrovascular vessel, improve body fat metabolism, enhancing human body immunity power, there is auxiliary lipid-lowering function.
Detailed description of the invention
Below in conjunction with embodiment, technical scheme of the present invention is further described; but be not limited thereto; everyly technical solution of the present invention modified or equivalent to replace, and not departing from the spirit and scope of technical solution of the present invention, all should be encompassed in protection scope of the present invention.
Embodiment 1:
What the present embodiment provided consists of the following composition containing Auricularia extract, the compositions with effect for reducing blood fat: Auricularia extract (comprising the melanin 70mg that the Auricularia polycose 550mg of purity 40% and purity are 40%), Monas cuspurpureus Went extract 330mg, Folium Ginkgo extract 90mg, Fructus Crataegi extract 150mg, Pollen Tyjphae extract 150mg, Radix Glycyrrhizae extract 150mg.
Embodiment 2:
What the present embodiment provided consists of the following composition containing Auricularia extract, the compositions with effect for reducing blood fat: Auricularia extract (comprising the melanin 90mg that the Auricularia polycose 1000mg of purity 30% and purity are 40%), Monas cuspurpureus Went extract 110mg, Folium Ginkgo extract 160mg, Fructus Crataegi extract 80mg, Pollen Tyjphae extract 80mg, Radix Glycyrrhizae extract 80mg.
Embodiment 3:
What the present embodiment provided consists of the following composition containing Auricularia extract, the compositions with effect for reducing blood fat: Auricularia extract (comprising the melanin 50mg that the Auricularia polycose 800mg of purity 40% and purity are 30%), Monas cuspurpureus Went extract 250mg, Folium Ginkgo extract 120mg, Fructus Crataegi extract 100mg, Pollen Tyjphae extract 100mg, Radix Glycyrrhizae extract 100mg.This is the consumption per day (1.52g) of 1 person-time, divides and takes for 2 times.
Preparation method:
(1) black fungus powder is broken to 200 orders, even by the deionized water and stirring of 40 times of volumes, place 2h, room temperature adopts High Pressure Difference method (solution is forced into 1.0Mpa, and rapid release of pressure is to atmospheric pressure state in 0.1s) to extract 2 times, filters, filter vacuum concentrates, dry, pulverize, obtain Auricularia polycose extract; The sodium hydroxide solution adjustment solution ph that filtering residue adds 4 times of volumes is 10.5, and leave standstill 1.5h, filter, supernatant hydrochloric acid adjusted to ph is 3.2, leaves standstill 1.5h, and filter, pellet frozen dry, pulverize, and obtains Auricularia melanin.
(2) Folium Ginkgo, Fructus Crataegi and Pollen Typhae all prepare extract according to following extraction process: raw material pulverizing to 100 order, be extract 3 times under the alcoholic solution ultrasound wave 300W of 60% by 15 times of volume fractions, each 0.5h, merge extractive liquid, filters, filtrate recycling ethanol, concentrated, dry, pulverize, obtain alcohol extract.
(3) the cholamine solution (0.1% ammonia, 25% ethanol) adding 10 times of volumes in Radix Glycyrrhizae carries out reflux, extract, 1.5h at 80 DEG C of temperature, filters, and dries, and pulverizes, obtains Radix Glycyrrhizae extract.
(4) Monas cuspurpureus Went extract preparation technology is: 5 constant virtues organic rice, immersion, steaming and decocting, cooling, the purple leaf Monascus anka Nakazawa et sato of inoculation, natural cultivation and fermentation, production Monas cuspurpureus Went, be crushed to 100 orders, adopt the alcoholic solution of 80% of 20 times of volumes, extract 2 times under ultrasound wave 500W, each 1.0h, merge extractive liquid, filters, filtrate recycling ethanol, concentrated, dry, pulverize, obtain alcohol extract.The content of the functional red yeast rice effective ingredient of this explained hereafter is clearer and more definite, and effect is more definite.Not containing citrinin, have no side effect, reduce burden of liver, it is easier to absorb, and effect is more remarkable.
(5) by Auricularia polycose, Auricularia melanin, Fructus Crataegi extract, Semen Ginkgo extrac, Radix Glycyrrhizae extract, Pollen Tyjphae extract and Monas cuspurpureus Went extract, prepare hard capsule, or with pharmaceutic adjuvant be mixed together make in oral formulations, hard capsule, soft capsule, tablet, granule, powder, pill, teabag, liquid beverage according to a conventional method one or more, can apply in preparation blood fat reducing medicine, health food.
Zoopery:
Experimental technique: adopt SD rat to be provided by Shanghai Slac Experimental Animal Co., Ltd., production licence number is SCXK (Shanghai) 2012-0002; Body weight 200-250g, male, random packet, is respectively normal group, model group, positive control drug Xuezhikang 0.2gkg
-1group, and Auricularia extractive compound preparation 0.135,0.27,0.54gkg
-1basic, normal, high 3 dosage groups, often organize 10.Except normal group gives drinking water, each group rat is all fed with high lipid food (Nantong Te Luofei feedstuff), every day 3 times, continuous 3 weeks.Model group compares with normal group, TC and LDL-C all obviously raises, and has significant difference (P<0.01), shows that high lipid food makes the success of Rat Experimental hyperlipidemia animal model.The rat be up to the standards starts test: gastric infusion, every day, and except Normal group, each group rat continues to feed with high lipid food.Each administration group to the basic, normal, high dosage group of Auricularia extractive compound preparation (dosage is respectively 0.135,0.27,0.54gkg
-1), gastric infusion capacity 20mLkg
-1.Positive drug Xuezhikang 0.2gkg
-1, gastric infusion capacity 10mLkg
-1.Continuous 8 weeks.Each group of rat blood sampling, separation of serum, adopts triglyceride, T-CHOL, low-density lipoprotein cholesterol (LDL-C), HDL-C (HDL-C) testing cassete (Beijing North Hua Tai clinical reagent company limited) to measure each content.
Experimental result: compare with model group, positive control Xuezhikang group can effectively reduce TG, TC and LDL-C level, and difference has significant (P<0.01); Each dosage group serum High Density Lipoprotein Cholesterol (HDL-C) is not significantly lower than model control group; The basic, normal, high dosage group of compound Jew ' s-ear extract can obviously reduce TG, TC and LDL-C level, except low dose group reduces low-density lipoprotein cholesterol (LDL-C) difference comparatively remarkable (P<0.05), respectively group and model group comparing difference all extremely significantly (P<0.01), and respectively organize HDL-C level and model group difference is not remarkable for other.Each experimental group blood lipid level testing result is as shown in table 1.
Table 1 Auricularia compound preparation on the impact of hyperlipidemia rats blood lipid level (
) mmolL
-1
Note: compare with blank group
ap<0.01,
bp<0.05; Compare with model group,
cp<0.01,
dp<0.05.
Compositions has the effect reducing serum triglycerides, T-CHOL, low density lipoprotein, LDL, and HDL-C is slightly improved, there is remarkable hypolipemic function, and lipid-lowering effect is better than the lipid-lowering effect (see table 2) of any a kind of extract in alone compositions.
Table 2 Auricularia compound preparation and single preparations of ephedrine on the impact of hyperlipidemia rats blood lipid level (
) mmolL
-1
Note: compare with blank group
ap<0.01,
bp<0.05; Compare with model group,
cp<0.01,
dp<0.05.
Human feeding trial:
For checking therapeutic effect of the present invention, choose 200 routine hyperlipemic patients, selected patient all meets hyperlipemia diagnostic criteria.Wherein male 75 example, women 75 example, 40 ~ 63 years old age, 48 years old mean age.Be divided into 4 groups at random, often organize 50 people.First group of compositions treatment prepared by embodiment 1; Second group of compositions treatment prepared by embodiment 2; The 3rd group of compositions treatment prepared by embodiment 3; 4th group is that blank group gives placebo.The course for the treatment of 90d, respectively before the treatment after all on an empty stomach after 12h in early morning venous blood samples to measure TC, TG, LDL-C, HDL-C, the heart, Liver and kidney function and blood, urine, feces conventional etc.Chest X-rays, electrocardiogram, Abdominal B type ultrasonography inspection is carried out before on-test.The results are shown in Table 3.
Indices judges as follows:
(1) effective: TC reduces >10%; TG reduces >15%; HDL-C rising >0.104mmol/L.
(2) invalid: not reach effective standard person.
Table 3 human body foretastes test group result of the test (n=50)
By to each group after test individual carry out blood lipids index inspection and blood, urine, feces result that is conventional, Liver and kidney function inspection to carry out each embodiment total effective rate of analysiss discovery be more than 96.0%, rate of side effects and half a year relapse rate be 0.That Liver and kidney function check result shows test group hepatic and renal function is also more healthy than the physical signs before taking compositions, and general performance compositions has the outstanding feature of efficacy enhancing and toxicity reducing.
Conclusion:
The present invention has better effect to the generation of hyperlipemia and treatment.
Shown by zoopery: 1) model control group and blank group compare, serum total cholesterol or low-density lipoprotein cholesterol raise, and difference has significance, and decision model is set up; 2) each dosage group compares with model control group, middle and high dosage group serum total cholesterol, serum triglycerides, low-density lipoprotein cholesterol reduce, difference has significance, and each dosage group serum High Density Lipoprotein Cholesterol is not significantly lower than model control group, show that this given the test agent auxiliary lipid-lowering function results of animal is positive.
Shown by human feeding trial assay: 1) each embodiment total effective rate of compositions is more than 96.0%, rate of side effects and half a year relapse rate be 0; 2) check result such as Human Physiology index and Liver and kidney function shows that composition in its entirety has showed the outstanding feature with efficacy enhancing and toxicity reducing.
Claims (9)
1., containing Auricularia extract, a compositions with effect for reducing blood fat, it is characterized in that described compositions consists of the following composition: Auricularia polycose 400 ~ 1100mg, Auricularia melanin 35 ~ 100mg, Monas cuspurpureus Went extract 95 ~ 350mg, Folium Ginkgo extract 75 ~ 180mg, Fructus Crataegi extract 55 ~ 170mg, Pollen Tyjphae extract 55 ~ 170mg, Radix Glycyrrhizae extract 70 ~ 170mg.
2. according to claim 1 containing Auricularia extract, the compositions with effect for reducing blood fat, it is characterized in that described compositions consists of the following composition: Auricularia polycose 550mg, melanin 70mg, Monas cuspurpureus Went extract 330mg, Folium Ginkgo extract 90mg, Fructus Crataegi extract 150mg, Pollen Tyjphae extract 150mg, Radix Glycyrrhizae extract 150mg.
3. according to claim 1 containing Auricularia extract, the compositions with effect for reducing blood fat, it is characterized in that described compositions consists of the following composition: Auricularia polycose 1000mg, melanin 90mg, Monas cuspurpureus Went extract 110mg, Folium Ginkgo extract 160mg, Fructus Crataegi extract 80mg, Pollen Tyjphae extract 80mg, Radix Glycyrrhizae extract 80mg.
4. according to claim 1 containing Auricularia extract, the compositions with effect for reducing blood fat, it is characterized in that described compositions consists of the following composition: Auricularia polycose 800mg, melanin 50mg, Monas cuspurpureus Went extract 250mg, Folium Ginkgo extract 120mg, Fructus Crataegi extract 100mg, Pollen Tyjphae extract 100mg, Radix Glycyrrhizae extract 100mg.
5. the preparation method containing Auricularia extract, have the compositions of effect for reducing blood fat described in the arbitrary claim of claim 1-4, is characterized in that described preparation method step is as follows:
(1) pulverized by Auricularia, even by the deionized water and stirring of 30 ~ 60 times of volumes, place 1 ~ 3h, room temperature adopts High Pressure Difference method to extract 1 ~ 3 time, and filter, filter vacuum concentrating under reduced pressure, dry, pulverize, and obtains Auricularia polycose extract; The sodium hydroxide solution adjustment solution ph that filtering residue adds 2 ~ 5 times of volumes is 10.0 ~ 11.0, and leave standstill 1 ~ 2h, filter, supernatant hydrochloric acid adjusted to ph is 3.0 ~ 3.5, leaves standstill 1 ~ 2h, and filter, pellet frozen dry, pulverize, and obtains Auricularia melanin;
(2) Folium Ginkgo, Fructus Crataegi and Pollen Typhae all prepare extract according to following extraction process: raw material pulverizing, be extract 2 ~ 3 times under the alcoholic solution ultrasound wave 200 ~ 500W of 50 ~ 95% by 10 ~ 20 times of volume fractions, each 0.5 ~ 1.0h, merge extractive liquid, filters, filtrate recycling ethanol, concentrated, dry, pulverize, obtain alcohol extract;
(3) the cholamine solution adding 6 ~ 20 times of volumes in Radix Glycyrrhizae carries out reflux, extract, 1 ~ 2h at 70 ~ 90 DEG C of temperature, filters, and dries, and pulverizes, obtains Radix Glycyrrhizae extract;
(4) Monas cuspurpureus Went is pulverized, and adopts the alcoholic solution of 60 ~ 85%, extracts 2 ~ 3 times, each 0.5 ~ 1.0h, merge extractive liquid, under ultrasound wave 200 ~ 500W, filters, filtrate recycling ethanol, concentrated, dry, pulverize, obtains alcohol extract;
(5) Auricularia polycose, Auricularia melanin, Fructus Crataegi extract, Semen Ginkgo extrac, Radix Glycyrrhizae extract, Pollen Tyjphae extract and Monas cuspurpureus Went extract are mixed, obtain containing Auricularia extract, the compositions with effect for reducing blood fat.
6. according to claim 5 containing Auricularia extract, the preparation method with the compositions of effect for reducing blood fat, it is characterized in that described Auricularia is the Auricularia sporophore that black 29 kinds carry out autumn culture.
7. according to claim 5 containing Auricularia extract, the preparation method with the compositions of effect for reducing blood fat, it is characterized in that described Auricularia polycose and melanic purity are 30 ~ 40%.
8. according to claim 5 containing Auricularia extract, the preparation method with the compositions of effect for reducing blood fat, it is characterized in that the grinding particle size of described Auricularia is 150 ~ 240 orders.
9. according to claim 5 containing Auricularia extract, there is the preparation method of the compositions of effect for reducing blood fat, it is characterized in that described Folium Ginkgo, Fructus Crataegi, Pollen Typhae and Monas cuspurpureus Went grinding particle size be 100 ~ 150 orders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510816925.8A CN105395919B (en) | 2015-11-23 | 2015-11-23 | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510816925.8A CN105395919B (en) | 2015-11-23 | 2015-11-23 | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105395919A true CN105395919A (en) | 2016-03-16 |
| CN105395919B CN105395919B (en) | 2019-03-19 |
Family
ID=55461907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510816925.8A Active CN105395919B (en) | 2015-11-23 | 2015-11-23 | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395919B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107319555A (en) * | 2017-07-21 | 2017-11-07 | 韩希典 | A kind of food of reducing blood lipid |
| CN108743632A (en) * | 2018-04-27 | 2018-11-06 | 浙江工业大学 | Method for removing ginkgolic acid in ginkgo by ultrasonic assistance |
| CN110643655A (en) * | 2019-10-23 | 2020-01-03 | 河北科技大学 | Hawthorn flavone chelated sugar and preparation method and application thereof |
| CN111096447A (en) * | 2019-12-30 | 2020-05-05 | 广州泽力医药科技有限公司 | Tremella pulp, preparation method and application thereof, thickener and preparation method thereof |
| CN113694105A (en) * | 2021-10-11 | 2021-11-26 | 于洪林 | Composition with blood fat reducing function and application thereof |
| CN115137069A (en) * | 2022-09-06 | 2022-10-04 | 山东向日葵生物工程有限公司 | Lactobacillus delbrueckii subspecies bulgaricus SF-L-18 fermented product and preparation method and application thereof |
| CN116098981A (en) * | 2023-01-10 | 2023-05-12 | 辽宁农业职业技术学院 | Medicinal and edible traditional Chinese medicine composition for reducing blood fat and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104187678A (en) * | 2014-09-11 | 2014-12-10 | 浙江方格药业有限公司 | Health composition for reducing blood fat and production method of health composition |
-
2015
- 2015-11-23 CN CN201510816925.8A patent/CN105395919B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104187678A (en) * | 2014-09-11 | 2014-12-10 | 浙江方格药业有限公司 | Health composition for reducing blood fat and production method of health composition |
Non-Patent Citations (2)
| Title |
|---|
| 张朝波等: "银曲胶囊调节血脂药效学研究", 《安徽医药》 * |
| 郭志华: "活血降脂汤治疗高脂血症46例小结", 《湖南中医杂志》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107319555A (en) * | 2017-07-21 | 2017-11-07 | 韩希典 | A kind of food of reducing blood lipid |
| CN108743632A (en) * | 2018-04-27 | 2018-11-06 | 浙江工业大学 | Method for removing ginkgolic acid in ginkgo by ultrasonic assistance |
| CN110643655A (en) * | 2019-10-23 | 2020-01-03 | 河北科技大学 | Hawthorn flavone chelated sugar and preparation method and application thereof |
| CN110643655B (en) * | 2019-10-23 | 2022-04-26 | 河北科技大学 | Hawthorn flavone chelated sugar and preparation method and application thereof |
| CN111096447A (en) * | 2019-12-30 | 2020-05-05 | 广州泽力医药科技有限公司 | Tremella pulp, preparation method and application thereof, thickener and preparation method thereof |
| CN113694105A (en) * | 2021-10-11 | 2021-11-26 | 于洪林 | Composition with blood fat reducing function and application thereof |
| CN115137069A (en) * | 2022-09-06 | 2022-10-04 | 山东向日葵生物工程有限公司 | Lactobacillus delbrueckii subspecies bulgaricus SF-L-18 fermented product and preparation method and application thereof |
| CN116098981A (en) * | 2023-01-10 | 2023-05-12 | 辽宁农业职业技术学院 | Medicinal and edible traditional Chinese medicine composition for reducing blood fat and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105395919B (en) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN102114102B (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
| CN102697982B (en) | Composition having auxiliary blood fat reducing effect and preparation method thereof | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN104173451B (en) | The application in blood sugar lowering medicine and health food of a kind of natural drug composition | |
| CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN103211957B (en) | Alcohol relieving and liver protecting composition and application thereof | |
| CN101933965A (en) | Mugwort extract and preparation process thereof, and application in controlling postmeal gucose | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN110680840B (en) | Application of small blackberry extract in preparation of hypolipidemic drugs | |
| CN103610048A (en) | Health-care food with assistant protecting function to chemical liver injury and preparation method thereof | |
| JP2007131605A (en) | Indefinite complaint-improving composition and food | |
| CN101040905B (en) | Medicine made by selfheal for reducing blood sugar | |
| CN109125623A (en) | It is a kind of for treating the pharmaceutical composition of hepatopathy | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| WO2013155997A1 (en) | Blood lipid-regulating red yeast ligusticum chuanxiong pharmaceutical composition and preparation method therefor | |
| CN109453249B (en) | Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms | |
| KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast | |
| CN106309616A (en) | Medicine with hypolipidemic effect | |
| CN105031033A (en) | Food or healthcare product or medicine composition containing lycium barbarum leaves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |